Drug intelligence / Profile preview

SRP-1005

Development stage: Phase 1
Lead developer: Sarepta Therapeutics
Administration: Subcutaneous

Overview

SRP-1005 is an investigational therapeutic agent being developed by Sarepta Therapeutics for the treatment of Huntington's disease. Specific information regarding its molecular modality, mechanism of action, and biological target has not been publicly disclosed as of October 2025. It is planned for Phase I clinical trials, which are anticipated to begin in the first half of 2026[3][7].

Brand names: SRP-1005SRP1005SRP 1005
Other names: SRP-1005SRP1005SRP 1005

Targets

TFRC (Transferrin Receptor)HTT mRNA (HTT / Huntingtin gene)

Beyond the preview

Go deeper on SRP-1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRP-1005.

Explore the full profile